



PRESS RELEASE

## Bulletin from Moberg Pharma's Extraordinary General Meeting

**STOCKHOLM, 9 October 2023. Moberg Pharma AB (publ)'s (OMX: MOB) (the "Company") Extraordinary General Meeting took place today. The Extraordinary General Meeting resolved to approve the Board of Directors' resolution to issue warrants.**

The Extraordinary General Meeting resolved to approve the Board of Directors' resolution from 8 September 2023 on an issue of 664,370 warrants of series 2023:1 to guarantors who chose to receive their guarantee commission in the form of units in the rights issue of units, consisting of ordinary shares and warrants of series 2023:1, resolved by the Board of Directors on 28 June 2023.

Each warrant of series 2023:1 entitles the holder to subscribe for one (1) new ordinary share in the Company during the period 5 June 2024 up to and including 19 June 2024. The subscription price for subscription of ordinary shares with the support of warrants of series 2023:1 will correspond to 70 percent of the volume-weighted average price in the Company's ordinary share during the period from and including 20 May 2024 up to and including 31 May 2024. However, the subscription price can at minimum amount to the quota value of the Company's shares, corresponding to approximately SEK 1.0 per ordinary share.

**For additional information, please contact:**

Anna Ljung, CEO, telephone: 070 - 766 60 30, e-mail: [anna.ljung@mobergpharma.se](mailto:anna.ljung@mobergpharma.se)

Mark Beveridge, VP Finance, telephone: 076 - 805 82 88, e-mail: [mark.beveridge@mobergpharma.se](mailto:mark.beveridge@mobergpharma.se)

**About this information**

The information was submitted for publication, through the agency of the contact persons set out above, at 11:00 am CEST on 9 October 2023.

**About Moberg Pharma, [www.mobergpharma.com](http://www.mobergpharma.com)**

Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company's asset, MOB-015, is a novel topical treatment for onychomycosis, for which the first market approval has recently been obtained. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the Company's shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).